New Zinbryta data shows improvements on key measures of MS disease activity

US firms Biogen (Nasdaq: BIIB) and AbbVie (NYSE: ABBV) have reported positive results in a Phase III study of once-monthly investigational drug Zinbryta (daclizumab high-yield process) in multiple sclerosis.

Zinbryta improved results on key measures of multiple sclerosis disease activity in patients with relapsing-remitting multiple sclerosis compared to interferon beta-1a 30mcg intramuscular injection. Zinbryta was shown to increase the percentage of patients achieving no evidence of clinical and MRI disease activity, improve cognitive processing speed and reduce 24-week confirmed disability progression across a broad range of subgroups at two years. These results support the known benefit-risk profile of Zinbryta and indicate that adverse events did not appear to increase over time.

Ludwig Kappos, lead investigator for the DECIDE study, said: “The new DECIDE data presented at ECTRIMS [Congress of the European Committee for Treatment and Research in Multiple Sclerosis] provide further insight into the potential of daclizumab HYP to reduce MS disease activity, including the efficacy it has demonstrated in reducing MS relapse rates, disability progression and brain lesion development. Over the two years of data we analyzed, nearly twice as many patients treated with daclizumab HYP had no evidence of MS disease activity compared to those taking an approved MS treatment.”